World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 25 November 2019
Main ID:  EUCTR2005-004582-41-GB
Date of registration: 27/01/2006
Prospective Registration: Yes
Primary sponsor: University of Leeds
Public title: Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA
Scientific title: Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA
Date of first enrolment: 24/03/2006
Target sample size: 15
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004582-41
Study type:  Interventional clinical trial of medicinal product
Study design: 
Controlled: yes
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
•Male and female patients aged between 18 and 80 years.
•Diagnosis of rheumatoid arthritis (1987 revised ACR criteria) confirmed at least 6 months prior screening
•Persisting RA activity despite treatment with leflunomide for at least 16 weeks with 20 mg/day or 10 mg/day. Dose stable for four weeks prior to baseline
•Subjects with active RA at baseline defined as: DAS 28 >5.1
•Rheumatoid factor positive

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1.Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic arthritis, systemic lupus erythematous, or any arthritis with onset prior to 16 years of age.
2.Suspicion of diagnosis of tuberculosis (positive tuberculosis test (>5mm induration if previous BCG or >10mm if no previous BCG) or abnormal chest x-ray).
3.Patients with concomitant medical condition which would in the investigator’s opinion compromise the patient’s ability to tolerate, absorb, metabolise or excrete the study medication.
4.Patients with serious infections within 3 month of enrollment (screening) or persistent infections.
5.Patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ)).
6.Patients with malignancy (other than excised basal cell carcinoma) within the last 5 years before study entry (screening).
7.Patients with history of Felty’s syndrome, uncontrolled diabetes, uncontrolled hypertension, unstable ischaemic heart disease, active bowel disease, active peptic ulcer disease, recent stroke (within three month before study entry (screening)), or other condition which, in the opinion of the investigator, would put the patient at risk to participate in the study.
8.Known positive serology for hepatitis B or C, or HIV
9.Patients with acute major trauma.
10.Patients with body weight < 45 kg.
11.Clinically relevant cardiovascular, hepatic, neurologic (such as multiple sclerosis, optic neuritis etc.), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult.
12.Impaired hepatic function, as shown by ALT or ALP more than or equal to 1,5 times the laboratory upper limit of normal or Serum albumin < 30 g/l.
13.Patients with significantly impaired bone marrow function as for example significant anaemia, leukopenia, neutropenia or thrombocytopenia.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Active Rheumatoid Arthritis
Intervention(s)

Trade Name: Mabthera
Product Name: Mabthera
Product Code: Rituximab
Pharmaceutical Form: Concentrate for solution for infusion

Trade Name: Arava
Product Name: Arava
Product Code: Leflunomide
Pharmaceutical Form: Film-coated tablet

Trade Name: Solu-Medrone 2 Gram
Product Name: Solu-Medrone 2mg
Product Code: Methylprednisolone
Pharmaceutical Form: Powder for injection*

Primary Outcome(s)

Primary end point(s): Efficacy will be defined by Disease Activity Score (DAS28)
The DAS28 calculation is based on the evaluation of four variables:
-28 tender joints
-28 swollen joins
-Erythrocyte Sedimentation Rate (ESR)
-Patient’s general health status, as assessed by a 100 mm visual analogue scale (VAS)
Investigators global assessment (VAS )
Patient pain assessment (VAS)
Rheumatoid Arthritis Quality of Life scale (RAQoL)
Health Assessment Questionnaire (HAQ)
CRP
Rheumatoid Factor titre
Radiological assessments (plain X-ray, HRUS, MRI)
Early morning stiffness
Main Objective: Primary objective is to assess safety of rituximab combined with leflunomide. Safety will be evaluated by the frequency of Adverse Events and the outcome of laboratory blood monitoring.
Secondary Objective: Secondary objective is to assess efficacy of rituximab combined with leflunomide in active RA patients
Secondary Outcome(s)
Secondary ID(s)
RTX/LFU rheumatoid arthritis.
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey